HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications

TUCSON, Ariz. and PARIS , Oct. 26, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, and OmiCure ® , a leading European digital health company that